Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Medicine
FDA Approves Datopotamab Deruxtecan for Certain Triple-Negative Breast Cancers
The FDA approved datopotamab deruxtecan-dlnk for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibitor therapy.
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
The FDA approved datopotamab deruxtecan-dlnk on 22 May for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibitor therapy.
FDA said efficacy was evaluated in TROPION-Breast02, a randomized trial comparing the antibody-drug conjugate with investigator’s choice of chemotherapy.
The approval adds another antibody-drug conjugate option in a breast-cancer subtype where treatment choices are often limited by disease biology and prior therapy.
Sourcing note: Indication, trial name and comparator details are from FDA. This article does not provide clinical advice.
Why It Matters
Triple-negative breast cancer remains difficult to treat. New approvals in defined patient groups show how oncology progress often arrives through narrower, trial-specific indications.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDADatopotamab DeruxtecanTriple-Negative Breast CancerDatrowayOncology